PubMed

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

Rosenberg SA, Lotze MT, Mulé JJ.

Ann Intern Med. 1988 Jun;108(6):853-64. Review.PMID: 3285747 [PubMed - indexed for MEDLINE]Related articles

The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.

Rosenberg SA.

Ann Surg. 1988 Aug;208(2):121-35. Review.PMID: 3041925 [PubMed - indexed for MEDLINE]Related articlesFree article

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE.

Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5.PMID: 2679456 [PubMed - indexed for MEDLINE]Related articlesFree article

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Lafreniere R, Rosenberg SA.

Cancer Res. 1985 Aug;45(8):3735-41.PMID: 3893689 [PubMed - indexed for MEDLINE]Related articlesFree article

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.

N Engl J Med. 1987 Apr 9;316(15):889-97.PMID: 3493432 [PubMed - indexed for MEDLINE]Related articles

Development of new immunologic approaches to cancer therapy.

Rosenberg SA.

Blood Purif. 1988;6(2):69-76. Review.PMID: 3293619 [PubMed - indexed for MEDLINE]Related articles

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al.

N Engl J Med. 1985 Dec 5;313(23):1485-92.PMID: 3903508 [PubMed - indexed for MEDLINE]Related articles

Adoptive therapies: quo vadis?

Clark JW, Longo DL.

Pathol Immunopathol Res. 1988;7(6):442-58. Review.PMID: 3070530 [PubMed - indexed for MEDLINE]Related articles

Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.

Topalian SL, Rosenberg SA.

Acta Haematol. 1987;78 Suppl 1:75-6.PMID: 3124451 [PubMed - indexed for MEDLINE]Related articles

Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells.

van Haelst-Pisani CM, Pisani RJ, Kovach JS.

Mayo Clin Proc. 1989 Apr;64(4):451-65. Review.PMID: 2654502 [PubMed - indexed for MEDLINE]Related articles

Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.

Shiloni E, Lafreniere R, Mulé JJ, Schwarz SL, Rosenberg SA.

Cancer Res. 1986 Nov;46(11):5633-40.PMID: 3489526 [PubMed - indexed for MEDLINE]Related articlesFree article

Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.

Atzpodien J, Kirchner H.

Klin Wochenschr. 1990 Jan 4;68(1):1-11. Review.PMID: 2407894 [PubMed - indexed for MEDLINE]Related articles

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.

Lafreniere R, Rosenberg SA.

J Immunol. 1985 Dec;135(6):4273-80.PMID: 3877766 [PubMed - indexed for MEDLINE]Related articles

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.

Rosenberg SA.

J Biol Response Mod. 1984 Oct;3(5):501-11.PMID: 6389777 [PubMed - indexed for MEDLINE]Related articles

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al.

J Natl Cancer Inst. 1993 Apr 21;85(8):622-32. Erratum in: J Natl Cancer Inst 1993 Jul 7;85(13):1091. PMID: 8468720 [PubMed - indexed for MEDLINE]Related articles

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.

Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.

Cancer Res. 1986 Feb;46(2):676-83.PMID: 3484431 [PubMed - indexed for MEDLINE]Related articlesFree article

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.

Papa MZ, Mulé JJ, Rosenberg SA.

Cancer Res. 1986 Oct;46(10):4973-8.PMID: 3489517 [PubMed - indexed for MEDLINE]Related articlesFree article

Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Rosenberg SA, Lotze MT.

Annu Rev Immunol. 1986;4:681-709. Review. No abstract available. PMID: 3518753 [PubMed - indexed for MEDLINE]Related articles

Current approaches to the adoptive immunotherapy of cancer.

Yang JC, Rosenberg SA.

Adv Exp Med Biol. 1988;233:459-67.PMID: 3265581 [PubMed - indexed for MEDLINE]Related articles

A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C.

Surgery. 1986 Aug;100(2):262-72.PMID: 3526604 [PubMed - indexed for MEDLINE]Related articles